🟢 Xenetic Biosciences is trading 11.4% up today following proposed all-stock Santersus acquisition

Xenetic Biosciences is trading 11.4% up at $2.74 amid continued volatility following its proposed all-stock acquisition of Santersus AG.

• Santersus shareholders would own approximately 85% of the combined company, while existing Xenetic shareholders would retain about 15%.
• The transaction is expected to create Santersus Bio, focused on NET-targeting therapies, and remain Nasdaq-listed under the proposed SNTS ticker, subject to approvals.
• Shares fell 48.71% on September 16 and rose 12.33% on September 17.